Key Takeaways
- • Urologic Health closed an $11 million seed financing round to advance its non-invasive urodynamics diagnostic platform, the niu System, toward FDA 510(k) clearance and U.S. commercialization.
- • The round was led by an undisclosed strategic investor with participation from Edge Medical Ventures, SHD Partners, Longevity Venture Partners, and additional healthcare-focused investors.
- • The company's niu System eliminates catheterization in bladder function assessment by capturing clinically meaningful diagnostic data non-invasively, enabling more routine and repeatable urodynamic testing.
- • Co-founded by Adam Yaacov and Dr. Noam Omer, Urologic Health was incubated at the MEDX Xelerator venture studio (now EdgeLabs) and operates across the United States and Israel as part of the Edge Medical Ventures portfolio.
Summary
Urologic Health, a Jersey City-based medical device company, has secured $11 million in seed funding to support clinical validation, regulatory approval, and initial market entry for its proprietary non-invasive urodynamics technology. The financing round was led by an unnamed strategic investor alongside participation from established healthcare venture firms Edge Medical Ventures, SHD Partners, and Longevity Venture Partners, signaling confidence in the company's clinical and commercial trajectory within the medical diagnostics sector.
The company's core innovation is the niu System, a diagnostic platform designed to assess bladder function without requiring catheterization—a significant advancement in urodynamic testing, which traditionally relies on invasive procedures. By capturing bladder activity as actionable clinical data through non-invasive means, the technology enables more frequent and repeatable assessments, potentially expanding the addressable patient population and clinical use cases for urodynamic evaluation.
Urologic Health was co-founded by Adam Yaacov and Dr. Noam Omer, whose backgrounds encompass medical device development and AI-driven clinical solutions. The company emerged from the MEDX Xelerator venture studio, now operating as EdgeLabs, and maintains a dual operational footprint in the United States and Israel. As a portfolio company of Edge Medical Ventures, Urologic Health benefits from established venture infrastructure and healthcare sector expertise positioned to support its path through FDA 510(k) regulatory clearance and subsequent commercialization in the U.S. market.
The allocated capital will be directed toward clinical validation studies required for regulatory submission, navigation of the FDA 510(k) pathway for substantially equivalent devices, and preparation for initial commercialization activities. This funding stage positions the company to advance from development toward market-ready status, with the regulatory approval timeline likely to determine near-term commercial momentum within the urology diagnostic market.
The company's core innovation is the niu System, a diagnostic platform designed to assess bladder function without requiring catheterization—a significant advancement in urodynamic testing, which traditionally relies on invasive procedures. By capturing bladder activity as actionable clinical data through non-invasive means, the technology enables more frequent and repeatable assessments, potentially expanding the addressable patient population and clinical use cases for urodynamic evaluation.
Urologic Health was co-founded by Adam Yaacov and Dr. Noam Omer, whose backgrounds encompass medical device development and AI-driven clinical solutions. The company emerged from the MEDX Xelerator venture studio, now operating as EdgeLabs, and maintains a dual operational footprint in the United States and Israel. As a portfolio company of Edge Medical Ventures, Urologic Health benefits from established venture infrastructure and healthcare sector expertise positioned to support its path through FDA 510(k) regulatory clearance and subsequent commercialization in the U.S. market.
The allocated capital will be directed toward clinical validation studies required for regulatory submission, navigation of the FDA 510(k) pathway for substantially equivalent devices, and preparation for initial commercialization activities. This funding stage positions the company to advance from development toward market-ready status, with the regulatory approval timeline likely to determine near-term commercial momentum within the urology diagnostic market.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.